Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Garivulimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | EVQLVESGGGLVQPGGSLRLSCAVSGFSLTSYGVHWVRQAPGKGLEWVAVIWAGGSTNYADSVKGRFTISKDTSKNTVYLQMNSLRAEDTAVYYCAKPYGTSAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVGIVVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSNYPLYTFGQGTKVEIK | na | na | null | null | null | 2,020 | 2021 | CD274 | BeiGene | na | Solid tumours | na | na | null | E VQLVES GGG LV QPGG SLRLSCAV SGF SLTSYGVHWVRQ APGKGL EWVAVIWA GGSTNYADSVK GRFTISK DTSKN TVYLQMNS LRAEDT AVYYCA KPYGTSAMDYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQD VGIVVAWYQ QKPGKAP KLLIYWASIR HTGVPSRFSGSGSGT EFTLTISS LQPDDF ATYYCQ QYSNYP LYTF GQGT KVEI K |
Gatipotuzumab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS | DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK | na | na | null | null | null | 2,016 | 2017 | MUC1 | NEMOD Biotherapeutics;Glycotope | na | Ovarian cancer;Solid tumours;Fallopian tube cancer | na | GlycoExpress Technology | Gatipotuzumab and PankoMab are the same mAb | E VQLVES GGG LV QPGGS MRLSCVA SGFPFSNY WMNWVR QAPGKGL EWVGEIRLK SNNY TTHYAES VKG RFTISR DDSKNS LYLQMN SLKTEDT AVYYCT R HYYFD YWGQG TLVTVS S | D IVMT QSPLSNPVTPGEPA SISCR SSK SLLH SNG ITYFFWYL QKPGQSP QLLIYQM SNLASGVPDRFSGSGSGT DFTLRISRVE AEDV GVYYCAQ NLELPPTFGQGT KVEI K |
Gatralimab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFPFSNYWMNWVRQAPGKGLEWVGQIRLKSNNYATHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTPIDYWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK | na | na | 6obd:HL:BA | null | null | 2,019 | 2020 | CD52 | Sanofi | na | na | Multiple sclerosis | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGFPFSN YWMNWVR QAPGKGL EWVGQIRLK SNNYA THYAES VKG RFTISR DDSKNS LYLQMN SLKTEDT AVYYCT PIDYWGQG TTVTVS S | DI VMT QTP LSLSV TPGQP ASISC KSSQ SLLYS NGK TYLNWVLQ KPGQSPQ RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCVQ GS HFHT FGQGT KLEI K |
Gedivumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGVVQPGKSLRLSCAASGLTFSSYAVHWVRQAPGKGLEWVTLISYDGANQYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAVPGPVFGIFPPWSYFDNWGQGILVTVSS | EIVLTQSPATLSVSPGERATLSCRASQVISHNLAWYQQKPGQAPRLLIYGASTRASGIPARFSGSGSGTDYTLTITSLQSEDFAVYYCQHYSNWPPRLTFGGGTKVEIK | na | na | null | null | 4kvn:HL | 2,016 | 2017 | Influenza A HA | Genentech | na | na | Influenza A virus infections | na | null | E VQLVES GGG VV QPGK SLRLSC AASGL TFSSYAVHWVRQ APGKGL EWVTLISY DGANQ YYA DSVKG RFTISR DNSKN TVYLQMN SLRPEDT AVYYCA VPGP VFGI FPPWSYFDNWGQ GILVTVS S | E IVLT QSPA TLSV SPGE RATLSCR ASQ VISH N LAW Y QQKPGQAP RLLIYG ASTRASGIP ARFS GSGSGTD YTLTITS LQSED FAVYYCQ HYSNWPPR LTF GGG TKVEI K |
Gefurulimab | Bispecific Single Domains (VH-VH') | null | na;na | Phase-I | Active | EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS | na | EVQLVESGGGLVQPGGSLRLSCAASGRAHSDYAMAWFRQAPGQEREFVAGIGWSGGDTLYADSVRGRFTNSRDNSKNTLYLQMNSLRAEDTAVYYCAARQGQYIYSSMRSDSYDYWGQGTLVTVSS | na | None;None | None;None | None;None | 2,022 | na | C5;ALB | Alexion Pharmaceuticals | na | Myasthenia gravis;Proteinuria | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGRPVS NYAAAWF R QAPGKER EFVSAIN WQKTA TY ADSVK GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAAVFRVV APKTQYDYD Y WGQG TLVTVS S | null |
Gemtuzumab | Whole mAb ADC | G4 | Kappa | Approved | NFD | EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS | DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK | na | na | null | null | null | 2,016 | 2017 | CD33 | UCB;Celgene Corporation;Pfizer;University of California San Diego | Acute myeloid leukaemia | na | na | na | null | E VQLVQ SGA EVK KPGS SVKVSCK ASGY TIT DSN IHWVRQ APGQS LEWIGYIY PYNGGTDYNQKFKN RATLTV DNPTNT AYMELS SLRSEDT AFYYCV NGNP WLAYW GQG TLVTV SS | DI QLT QSPS TLSAS VGD RVTITCRA SESLDNY GIRFLTWFQ QKPGKAP KLLMYAA SNQGSGVPS RF SGSGSGT EFTLTISS LQPDDF ATYYCQ QTKEVPWSFGQGT KVEV K |
Geptanolimab | Whole mAb | G4 | Kappa | Preregistration | Active | QIQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLKWMGWISGYTREPTYAADFKGRFVISLDTSVSTAYLQISSLKAEDTAVYYCARDVFDYWGQGTLVTVSS | DIVLTQSPASLAVSPGQRATITCRASESVDNYGYSFMNWFQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEADDTANYYCQQSNADPTFGQGTKLEIK | na | na | null | null | null | 2,020 | 2021 | PDCD1 | Genor Biopharma;Appolomics | na | Peripheral T-cell lymphoma;Primary mediastinal B-cell lymphoma;Hepatocellular carcinoma | Lymphoma;Solid tumours | na | null | Q IQLVQ SGS E LKKPGA SVKVSCK ASGY TFTNFGMNWVRQ APGQGL KWMGWIS GYTREPT YAA DFKG RFVISL DTSVS TAYLQISS LKAEDT AVYYCA RDVFDYWGQG TLVTV SS | D IVLTQ SPA SLAV SPGQ RATITCRA SESVDNYG YSFMNWF QQKPGQPP KLLIYRA SNLESGVP ARF SGSGSRT DFTLTIN PVEADDTA NYYCQQ SNADPTFGQGT KLEI K |
Gevokizumab | Whole mAb | G2 | Kappa | Phase-III | Active | QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS | DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK | na | na | 4g6k:HL/4g6m:HL | null | null | 2,010 | 2011 | IL1B | IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA | na | Uveitis;Acne vulgaris;Acute coronary syndromes;Diabetic nephropathies;Giant cell arteritis;Labyrinthitis;Myositis;Osteoarthritis;Schnitzler syndrome;Scleritis;Colorectal cancer;Renal cell carcinoma | Rheumatoid arthritis;Cancer;Gout;Juvenile rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Pyoderma | na | null | Q VQLQE SGPGLVKPSQ TLSLTCSF SG FSLS TSGM GVGWIR QPSGKGL EWLAHIWW DGDESYNPSLK SRLTIS KDTSKN QVSLKITSVT AADT AVYFCA RNRYDPPW FVD WGQG TLVTVS S | DI QMT QSTS SLSAS VGD RVTITCR ASQD ISNYLSWYQ QKPGK AVKLLIYYT SKLHSGVPS R FSGSGSGTD YTLTISS LQQEDF ATYFCL QGK M LPW T FGQGT KLEI K |
Giloralimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | EVQLQESGPGLVKPSETLSLTCTVSGYSITSNYYWNWIRQPPGKGLEWMGYIRYDGSNNYNPSLKNRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSQSLENTNGNTFLNWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQVTHVPFTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | CD40 | AbbVie | na | Solid tumours | na | na | null | E VQLQE SGPGL V KPSE TLSLTCTV SG YSI TSN YYWNWIR QPPGKGL EWMGYIRY DGSNNYNPSLKN RVTISR DTSKN QFSLKLSS VTAADT AVYYCARLD YWGQG TTVTVS S | DI VMT QTP LSLSV TPGQP ASISCR SSQSL E NTNGN TFLNWYL QKPGQSP QLLIYRVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCLQVTHV PF T FGQG TKLEI K |
Gilvetmab | Canine Whole mAb | G2 | Kappa | Unknown | Active | EVQLVQSGGDLVKPGGSVRLSCVASGFNIKNTYMHWVRQAPGKGLQWIGRIAPANVDTKYAPKFQGKATISADTAKNTAYMQLNSLRAEDTAVYYCVLIYYDYDGDIDVWGQGTLVTVSS | DIVMTQTPLSLSVSLGEPASISCHASQNINVWLSWYRQKPGQIPQLLIYKASHLHTGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQGQSWPLTFGQGTKVEIK | na | na | null | null | null | 2,016 | 2017 | PDCD1 (Canine) | Merck | na | Canine Cancers | na | na | null | E VQLVQ SGGD LV KPGG SVRLSCVA SGFNIKNT YMHWVRQ APGKG LQWIGRI APANVDTKYAPKFQG KATISA DTAKN TAYMQLNSL RAEDTA VYYCVLIYY DYDGD IDVWGQGTLVTV SS | DI VMT QTPL SLSVS LGEP ASISCH ASQN INVWLSWY RQKPGQIP QLLIYK ASHLHTGVPDRFSGSGSGTD FTLRISRVE ADDAG VYYCQ QGQ S WP LTF GQGT KVEI K |
Gimsilumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS | EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIK | na | na | null | null | null | 2,017 | 2018 | CSF2 | Ludwig Institute for Cancer Research;Morphotek | na | na | Cancer;Rheumatoid arthritis | MORPHODOMA Technology | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFS RH W M HW LR QVPGKGP VWVSRI NGAGT SITYA DSVRG RFTISR DNANN TLFLQMN S L RADDT ALYFCAR ANS VWFR G LF DYWGQGTP VTV SS | E IVLT QSP VTLSV SPGE RVTLSCR ASQS VSTNLAWYQQK LGQGP RLLIYG ASTRATDIP ARF SGSGSE TEFTLTISS LQSED FAVYYCQQ YDKWPDTFGQGT KLEI K |
Ginisortamab | Whole mAb | G4 | Kappa | Phase-I/II | Active | QVQLVESGAEVKKPGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGTRLEIK | na | na | null | null | null | 2,021 | 2022 | GREM1 | UCB | na | Solid tumours | na | na | null | Q VQLVE SGA EVK KPGA TVKISCKV SGY TFTDYYMHWVQ QAPGKG LEWMGLV DPEDGE TIYAEKF QG RVTITA DTSTDT AYMELSS LRSEDT AVYYCAT DARGSGSYYPNHFD Y WGQG TLVTV SS | D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYS SNNK NYLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTIN SLQAED VAVYFCQQY YDTPTFGQG TRLEI K |
Girentuximab | Whole mAb Radiolabelled | G1 | Kappa | Phase-III | Discontinued | DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS | DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK | na | na | null | null | null | 2,009 | 2010 | CA9 | Centocor Inc;Heidelberg Pharma AG | na | na | Renal cancer | na | null | D VKLVE SGGG LVKL GG SLKLSC AASGF TFSNYYMSWVR QTPEKR LELVAAI NSDGG ITYYLD TVKG RFTISR DNAKN TLYLQMS SLKSEDT ALFYCA RHRSG YFSMDY WGQG TSVTVS S | DI VMT QSQ RFMST TVGD RVSITCK ASQN VVSAVAWYQ QKPGQSP KLLIYS ASNRYTGVPDRFTGSGSGTD FTLTIS NMQS EDLADFFCQQ YSNYPWTFGGGT KLEI K |
Glembatumumab | Whole mAb ADC | G2 | Kappa | Phase-III | Discontinued | QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK | na | na | null | null | null | 2,015 | 2016 | GPNMB | CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA) | na | na | Brain cancer;Breast cancer;Malignant melanoma;Osteosarcoma;Squamous cell cancer;Uveal melanoma | na | null | QV QLQE SGPGLVKPSQ TLSLTCTV SGGSIS SFNYYWSWIR HHPGKGL EWIGYIYYS GSTYSNPSLK SRVTISVD TSKN QFSLTLSS VTAADT AVYYCA RGYNWN YF DYWGQG TLVTVS S | E IVMT QSPA TLSV SPGER ATLSCRA SQSVDNN LVWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQQ YNNWPPWTFGQGT KVEI K |
Glenzocimab | Fab | G1 | Kappa | Phase-II/III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT | na | na | null | null | null | 2,018 | 2019 | GP6 | Acticor Biotech | na | Stroke;COVID-19 | na | na | (June '22: Corrected FWL3 sequence) | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGGI YPGNGDTSYNQK FQGRVTMTR DTSTS TVYMELS SLRSEDT AVYYC ARG TVV GD WYFDV WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR SSQSL E NSNGN TYLNWYQ QKPGKAP KLLIYRVS NRFSGVPS R FSGSGSGT DFTFTISS LQPEDI ATYYCLQLTH VPWTFGQGT KVEI T |
Glofitamab | Bispecific mAb with Domain Crossover | G1;G1 | Lambda;Kappa | Preregistration | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL | QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS | DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK | None;3pp3:HL/3pp4:HL | None;6y9a:HL | None;6y97:HL | 2,019 | 2020 | CD3E;MS4A1 | Roche | na | Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSTYAMNWVR QAPGKGL EWVSRI R SKYNNY ATYYA DSVKG RFTISR DDSKN TLYLQMNS LRAEDT AVYYCVR HGNFGNS YVSWFAYW GQG TLVTVS S | QA VVT QEP SLTV SPGG TVTLTC GSSTGA VTT SN YANWV QEKPGQA FRGLI GGTNKRAPGTPA RFS G SL LGGK AALTL SGAQPEDEA E YYCALWY SN LWVF GGGT KLTV L |
Golimumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK | na | na | 5yoy:RO:IF:QN:GD:HE:PM | null | null | 2,004 | 2005 | TNFA | Centocor;Centocor Ortho Biotech;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;Medarex | Ankylosing spondylitis;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis | Hearing disorders;Type 1 diabetes mellitus | Asthma;Cardiovascular disorders;Sarcoidosis;Uveitis | Medarex UltiMAb Mouse | null | Q VQLVES GGG VV QPGR SLRLSC AASG FIFS SY AMHWVRQ APGNGL EWVAFMSY DGSNKKYADS V K GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDRGIAAGGN YYYYGMDV WGQG TTVTVS S | E IVLT QSPA TLSL SPGE RATLSCR ASQS VY SYLAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPFTFGPGT KVD IK |
Golocdacimab | Whole mAb | G1 | Lambda | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDFKYHTHQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCALVWGTQGKGVRGWDYYYGMDVWGQGTTVTVSS | QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL | na | na | null | null | null | 2,022 | na | OLR1 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCKV SGY TLTELSMHWVR QAPGKGL EW MGGFD PED FK Y HTHQK F QG RVTMT EDTSTD TAYMELSS LRSEDT AVYYCALVW GTQGKGVRG WDYYY G MDV WGQG TTVTVS S | QSV V TQPPSVSGAPGQ RVTISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIYG NSNRPSGVPDRFSGSKSGTS A SLAIT GLQAEDEAD YYCQS YDSSLSG WVF GGGT KLTV L |
Gontivimab | Bispecific Single Domains (VH-VH'-VH') | na;na | na;na | Phase-II | Discontinued | DVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS | na | EVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS | na | None;None | None;None | None;None | 2,019 | 2020 | RSV gpF;RSV gpF | Ablynx | na | na | Respiratory syncytial virus infections | na | null | D VQLVE SGGG LVQ AGG SLSISCA ASGGSLS NYVLGWFR QAPGKER EFVAAIN WRGD ITI GPPNVEG RFTISR DNAKNT GYLQMN SLAPDDT AVYYC GAGTPLNPGA YIYD W S YDYWGRG TQVTVS S | null |
Gorivitug | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCSASGFTFSRYAMYWVRQAPGKGLEYVSAISSDGGSTYDADSVKGRFTISRANSKNTLYLQMSSLRAEDTAVYYCVKGLRELLYYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRAGQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPFTFGPGTKVDIK | na | na | null | null | null | 2,022 | na | SARS-CoV-2 Spike RBD | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGG SLRLSCS ASGF TFSRYAMYWVRQ APGKG LEYVSAIS SDGGST Y DADSVK GRFTISR ANSKN TLYLQMSS LRAEDT AVYYCV KG LRELLYYYY GMDVWGQG TTVTVS S | DIQMTQSPSS LSA SVGD RVTITC RAGQS ISSFLNWYQ QKPGKAP KLLIYAA SSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYY C QQSYITPF T FGPGT KVDI K |
Gosuranemab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | EVHLVESGGALVKPGGSLRLSCAASGFSFSKYGMSWVRQAPGKGLEWVATISSSGSRTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCSISWDGAMDYWGQGTTVTVSS | DVVMTQSPLSLPVTLGQPASISCKSSQSIVHSNGNTYLEWYLQKPGQSPQLLVYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCFQGSLVPWAFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | MAPT | Biogen;Bristol-Myers Squibb;iPierian | na | na | Cardiovascular disorders;Metabolic disorders;Alzheimer's disease;Progressive supranuclear palsy;Neurodegenerative disorders | na | null | E VHLVE SGG ALV KPGG SLRLSC AASGF SF SKYG MSWVRQ APGKG LEWVATIS SSGS RTY YPDSVK GRFTISR DNAKN TLYLQMN SLRAEDT AMYYCSISW DGAMDY W GQG TTVTVS S | DV VMT QSPLSLP VT LGQPA SISC KSSQ SIVH SNGN TYLEWYL QKPGQSP QLLVYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDVG TYYCF QGS L VPWAFGGG TKVEI K |
Gremubamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSS | AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPWTFGQGTKVEIK | QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWGQGTMVTVSS | DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGAWNWFGCGTKVEIK | None;None | None;None | None;None | 2,019 | 2020 | PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas) | MedImmune | na | na | Nosocomial pneumonia | na | (May '22) Added missing Y102 in Fv1 LC. | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMNWVR QAPGKGL EWVSAIT MSG ITAYYT DDVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK EEFLPGT HYYYGMDV WGQG TTVTVS S | AI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAP KLLIYS ASTLQSGVPS R FSGSGSGTD FTLTISS LQPEDF ATYYCL QDYNYPWTFGQGT KVEI K |
Gresonitamab | Bispecific scFv-scFv-scFc | G1;G1 | Kappa;Lambda | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYYGMDVWGQGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,021 | 2022 | CLDN18;CD3E | Amgen | na | GE Junction Cancer | na | BiTE Technology | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQ CLEWMGWI NPNSGGT KYAQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYC ARDR ITVA G TYYYYGMDV WGQG TTVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQGVN NW LAWYQ QKPGKAP KLLIYT ASSLQSGVPS R FSGSGSGTD FTLTIRS LQ PEDFAT YYC QQANSFP ITF GCGT RLEI K |
Grisnilimab | Whole mAb | G2a | Lambda | Phase-I/II | Active | QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLMWLGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARWAYFYGSSPYFFDYWGQGTTLTVSS | QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWCSNHLVFGGGTKLTVL | na | na | null | null | null | 2,020 | 2021 | CD7 | Xenikos | na | Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease | na | na | null | Q IQLVQ SGPELKKPGE TVKISCK ASGY TFTN YG MNWVK QAPGKG LMWLGWIN TYTGEPTYADDFKG RFAFSLE TSAS TAYLQIN NLKNEDTA TYFCARWAYFY GSSPY FFD YWGQG TTLTVS S | QA VVTQ E SALT TSPGE TVTLTCR SSTGA VTT SN YANWV QEKPDH LFTGLI GGTNNRAPGVPA RFSGSL IGDK AALTIT GAQTEDE AIYFCALWC SNH LVF GGGT KLTV L |
Gumokimab | Whole mAb | G1 | Kappa | Phase-II | Active | DVQLQESGPGLVKPSQTLSLTCTVSSYSFTSDYAWSWIRQPPGKGLEWIGYITYSGVTSYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARADYDSYYTMDYWGQGTSVTVSS | DVVMTQTPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCSQSTHFWTFGGGTKLEIK | na | na | null | null | null | 2,021 | 2022 | IL17A | Akeso Biopharma | na | Psoriasis | na | na | (June '22) Corrected CDRH2 sequence | DV QLQE SGPGLVKPSQ TLSLTCTVSS YSFTSDY AWSWIR QPPGKGL EWIGYITYS G VTS YNPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCAR ADYDS YYTMD YWGQG TSVTVS S | DV VMT QTPLSLP VT LGQPA SISC RSSQ SLVH SNGN TYLHWYLQ KPGQSP RLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GVYYCS QST HFWTF GGGT KLEI K |
Guselkumab | Whole mAb | G1 | Lambda | Approved | Active | EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS | QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL | na | na | 4m6m:HL/4m6n:HL | null | null | 2,013 | 2014 | IL23A | Janssen Biotech;MorphoSys;Taiho Pharmaceutical | Erythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis | Crohn's disease;Hidradenitis suppurativa;Ulcerative colitis;Familial adenomatous polyposis;Psoriasis;Giant cell arteritis;Lupus nephritis;Systemic scleroderma | Rheumatoid arthritis | MorphoSys HuCAL Phage Display | null | E VQLVQ SGA EVK KPGE SLKISC KGSGYSFSN YWIGWVRQ MPGKGL EWMGII DPSNSY TRY SPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCARWYY KPFD V WGQG TLVTVS S | QSVLTQPPSVSGAPGQ RVTISCT GSSSNIGSGY DVHWYQQ LPGTAP KLLIYG NSKRPSGVPDRFSGSKSGTS ASLAIT GLQSEDEAD YYCAS WTDGL SLVVF GGGT KLTV L |
Ianalumab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYDWVPKIGVFDSWGQGTLVTVSS | DIVLTQSPATLSLSPGERATLSCRASQFISSSYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQLYSSPMTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | TNFRSF13C | H. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis | na | Autoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus;Chronic lymphocytic leukaemia | na | POTELLIGENT Technology | (Feb '22) Residue 108 changed from Q to D according to amendment in RL83. (June '22) Corrected CDRL1/CDRL3 sequences. | QV QLQQ SGPGLVKPSQ TLSLTCAI SGDS V SSNSA AWGWIR QSPGRGL EWLGRIYYR SKWYNS YAVSVKSRITI NPDTSKN QFSLQL NSVTPEDT AVYYCA RYDWVP KIGVF DSWGQG TLVTVS S | D IVLT QSPA TLSL SPGE RATLSCR ASQFISS SYLSWY QQKPGQAP RLLIYG SSSRATGVP ARF SGSGSGT DFTLTIS SLE PEDF AVYY CQQL YSSPMTFGQGT KVEI K |
Ibalizumab | Whole mAb | G4 | Kappa | Approved | NFD | QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK | na | na | 3o2d:HL/7t0r:CB:HL | null | null | 2,007 | 2008 | CD4 | Biogen Idec;TaiMed Biologics;Theratechnologies | HIV-1 infections | na | na | na | null | QV QLQ QSGPE VV KPGA SVKMSCK ASGY TFTSYVIHWVR QKPGQGL DWIGYI NPYNDGTDYDEKFKG KATLT SDTSTS TAYMELS SLRSEDT AVYYCAR EKDNYATG AWFAYW GQG TLVTVS S | D IVMT QSPDS LAVS LGE RVTMNC KSSQ SLLYS TNQKN YLAWYQ QKPGQSP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISSV QAED VAVYYCQQYYSYRT FGGGT KLEI K |
Ibritumomab | Whole mAb | G1 | Kappa | Approved | NFD | QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSA | QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELK | na | na | 3bky:HL | null | null | 1,999 | 2000 | MS4A1 | Biogen;Schering;Spectrum Pharmaceuticals | Non-Hodgkin's lymphoma | na | Diffuse large B cell lymphoma;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Multiple myeloma | na | Sequence sourced through DrugBank. | QA YLQ QSGA ELV RPGA SVKMSCK ASGY TFTSYNMHWVK QTPRQGL EWIGAI YPGNGDTSYNQKFKG KATLTVD KSSST AYMQLS SLTSEDS AVYFCARVVYY SNS YWYFDVW GTGT TVTVS A | Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYMHWYQ QKPGSSPKP WIY APSNLASGVP ARFS GSGSGT SYSLTISRVE AEDA ATYYCQQWS FNPPTFGAGT KLEL K |
Icrucumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK | na | na | null | null | null | 2,010 | 2011 | FLT1 | ImClone Systems | na | na | Colorectal cancer;Urogenital cancer;Breast cancer | na | null | QA QVVES GG GVVQ SGR SLRLSC AASGF AFS SY GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVRG RFTISR DNSEN TLYLQMN SLRAEDT AVYYCAR DHYGSGV HHYFYYGLDV WGQG TTVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LE PEDF AVYYC QQ YGSSPL TF GGG TKVEI K |
Idactamab | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEIHHSGGANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGQGKNWHYDYFDYWGQGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASILKIGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSYSRTFGQGTKVEIK | na | na | null | null | null | 2,020 | 2021 | SLC1A5 | MedImmune | na | Acute myeloid leukemia;Multiple myeloma;Diffuse large B-cell lymphoma | na | na | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIHH SGGANYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGQGKNW HYDYF DYWGQG TLVTVS S | DIQ MT QSPS TLSAS VGD RVTITCR ASQ SIRSWLAWYQ QKPGKAP KLLIYKASILKIG VPSRFSGSGSGT EFTLTISS LQPDD FA TYYCQQYYSYS R T FGQGT KVEI K |
Idarucizumab | Fab | G1 | Kappa | Approved | NFD | QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS | DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK | na | na | 4jn2:HL:BA/4jn1:HL | null | null | 2,013 | 2014 | Dabigatran | Boehringer Ingelheim | Blood coagulation disorders | na | na | na | null | QV QLQE SGPGL V KPSE TLSLTCTV SGF SLTSYIVDWIR QPPGKGL EWIGVIWA GGSTGYNSA LRSRVSITK DTSKN QFSLKLSS VTAADT AVYYCA SA AYYSYY NYDG FAYW GQG TLVTV SS | DV VMT QSPLSLPV T LGQPA SISC KSSQ SLLYT DGK TYLYWFLQ RPGQSPR RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCLQS THFPHTFGGG TKVEI K |
Ieramilimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQARGQRLEWIGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYLQKPGQSPQLLIYYTSTLHLGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYNLPWTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | CD223 | Immutep Limited;Novartis | na | Breast cancer;Diffuse large B cell lymphoma;Malignant melanoma;Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASG FTLTNY G MNWVRQ ARGQ RLEWIGWIN TDTGEPT Y ADDFKG RFVFSL DTSVS TAYLQISS LKAEDT AVYYCA RNPPYYYGTNNAEA M DYWGQG TTVTVS S | DIQMTQSPSS LSA SVGD RVTITC SSSQ DISNYLNWYL QKPGQSP QLLIYYT S TLHL GVPSRFSGSGSGT EFTLTISS LQPDD FA TYYCQQ YYNLPWTFGQGT KVEI K |
Ifabotuzumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS | DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2017 | EPHA3 | Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute | na | Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma | na | POTELLIGENT Technology;Humaneering Technology | Ifabotuzumab is the new name for Fibatuzumab (PL115) | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYWMNWVR QAPGQGL EWMGDI YPGSGNTNYDEKFQG RVTMT RDTS ISTAYMELSR LRSDDT AVYYC ARGG YY EDFDSWGQG TTVTVS S | DIQ M TQSPS FLSA SVGD RVTITCR ASQG IISYLAWY QQKPEKAPK RLIYAA SSLQSGVPS RF SGSGSGT EFTLTISS LQPE DFA TYYC GQYANYPY T FGQGT KLEI K |
Ifinatamab | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYVMHWVRQAPGQGLEWMGYINPYNDDVKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWGYYGSPLYYFDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASSRLIYMHWYQQKPGQAPRPLIYATSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWNSNPPTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | CD276 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTNYVMHWVR QAPGQG LEWMGYI NPYNDDVKYNEKFKG RVTITA DESTS TAYMELS SLRSEDT AVYYCAR WGYYGSP LYYFD YWGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASSR LIYMHWYQ QKPGQAPRP LIYAT SNLASGIP ARFS GSGSGT DFTLTISS LEPED FAVYYCQQ WNSNPPTFGQGT KVEI K |
Iladatuzumab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2019 | CD79B | Roche | na | na | Non-Hodgkin's lymphoma | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY TFSSYWIEWVR QAPGKGL EWIGEI LPGGGDTNYN EIF KG RATFSA DTSKN TAYLQMN SLRAEDT AVYYCT RRVP IRLDY WGQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCK ASQS V DYEGD SFLN W Y QQKPGKAP KLLIYAA SNLESGVPS R FSGSGSGTD FTLTIS SLQPED F ATYYCQ QSNEDPL T FGQGT KVEI K |
Imalumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSSIGSSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGSQWLYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQRIMTYLNWYQQKPGKAPKLLIFVASHSQSGVPSRFRGSGSETDFTLTISGLQPEDSATYYCQQSFWTPLTFGGGTKVEIK | na | na | 6foe:HL:AB | null | null | 2,014 | 2015 | MIF | Cytokine PharmaSciences;Baxalta;Shire;Takeda | na | na | Solid tumours;Lupus nephritis;Colorectal cancer;Malignant ascites | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSIYSMNWVR QAPGKG LEWVSSI GSSGGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC AGSQ WLYGMDV WGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITC RSSQR I M TYLN WY QQKPGKAP KLLIFVAS HSQSGVPSRFRGSGSETD FTLTIS GLQPEDSA TYYCQ QSFWTPL T FGGGT KVEI K |
Imaprelimab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVTLKESGPVLVKPTETLTLTCTVSGFSLTSNAVSWVRQPPGKALEWIAAISSGGTTYYNSAFKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARRYGYGWYFDFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTINCKASQNIYNSLAWYQQKPGKAPKVLIFNANSLQTGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYSGYTFGQGTKLEIK | na | na | null | null | null | 2,017 | 2018 | MCAM | Neotope Biosciences;Onclave Therapeutics;Prothena;Prothena Corporation | na | na | Cancer;Inflammation;Psoriasis | na | null | QV TLK ESGP VLV KPTE TLTLTCTV SG FSL TSN AVSWVR QPPGKA LEWIAAIS SGGT TYY NSAFK SRLTIS RDTSKS QVVLTMT NMDPVDT AT YYCA R R YGYG WYFDF WGQG TLVTVS S | DIQMTQSPSSL SA SVGD RVTINC KAS QNIYNSLAWYQ QKPGKAP KVLIFN ANSLQTGIPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQF YSGY T FGQGT KLEI K |
Imgatuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK | na | na | null | null | null | 2,012 | 2013 | EGFR | GLYCART Biotechnology;Roche | na | na | Colorectal cancer;Head and neck cancer;Non-small cell lung cancer | GlycoMAb Technology | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGF TF TD YKIHWVRQ APGQG LEWMGYF NPNSGYS TYAQK FQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCARL SPGG YYVMD AWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQGI NNYLNWY QQKPGKAPK RLIYN TNNLQTGVPS R FSGSGSGT EFTLTIS SLQPEDF ATYYCLQ HNSFPTFGQGT KLEI K |
Imsidolimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMNWVRQAPRQGLEWMGMFHPTGDVTRLNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARTTSMIIGGFAYWGQGTLVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSKSLLHRNAITYFYWYLHKPGQPPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPLTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | IL36R | AnaptysBio | na | Generalised pustular psoriasis;Localised pustular psoriasis | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYWMN W VR QAPRQGL EWMGMF HPTGD VT RL NQKFKD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RTTS MIIGGFAYW GQG TLVTVS S | DI VMT QTP LSLSV TPGQP ASISCR SSKSLLHRNA ITYFYWYL HKPGQPP QLLIYQM SNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCA QNLELP LTF GGG TKVEI K |
Imvotamab | Pentameric IgM with Fused scFv | M | Kappa;Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK | EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHPSYGSGSPNFDYWGQGTLVTVSS | DIVMTQTPLSSPVTLGQPASISCRSSQSLVYSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCVQATQFPLTFGGGTKVEIK | None;None | None;None | None;None | 2,022 | na | CD3E;MS4A1 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFISYTMHWVR QAPGQG LEWMGYI NPRSGY TH YNQKLKDK ATLTA DKSAS TAYMELS SLRSEDT AVYYCAR S AYY DYDGF AYW GQG TLVTV SS | DI QMT QSPSS LSAS VGD RVTITCS ASSS VSYMNWY QQKPGKAPK RLIYD TSKLASGVPS RF SGSGSGT DFTLTISS LQPE DF ATYYCQQ WSSNPPTFGGGT KVEI K |
Inclacumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVRPGGSLRLSCAASGFTFSNYDMHWVRQATGKGLEWVSAITAAGDIYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGRYSGSGSYYNDWFDPWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK | na | na | None;None | None;None | None;None | 2,011 | 2012 | SELP | Genmab;Roche;Global Blood Therapeutics | na | na | Acute coronary syndromes;Myocardial infarction;Peripheral vascular disorders | Medarex UltiMAb Mouse | null | E VQLVES GGG LV RPGG SLRLSC AASGF TF SNYD MHWVRQ ATGKGL EWVSAIT AAGD IY YPGS VKGRFTIS RENAKN SLYLQMNS LRAGD TAVYYCA RGR Y SGSGSYYNDWFDPWGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWP LTF GGG TKVEI K |
Indatuximab | Whole mAb ADC | G4 | Kappa | Phase-II | Discontinued | QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQRPGHGLEWIGEILPGTGRTIYNEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRDYYGNFYYAMDYWGQGTSVTVSS | DIQMTQSTSSLSASLGDRVTISCSASQGINNYLNWYQQKPDGTVELLIYYTSTLQSGVPSRFSGSGSGTDYSLTISNLEPEDIGTYYCQQYSKLPRTFGGGTKLEIK | na | na | null | null | null | 2,011 | 2012 | SDC1 | Biotest AG | na | na | Bladder cancer;Breast cancer;Multiple myeloma | na | null | Q VQLQQ SGS ELM MPGA SVKISCKA TGY TF SN YWIEWVK QRPGHGL EWIGEI LPGTGR TIY NEKFKG KATFTAD ISSN TVQMQLS SLTSEDS AVYYCAR RDYYGN FYYAMD YWGQGT SVTVS S | DI QMT QSTS SLSA SLGD RVTISCS ASQG INNYLNW YQ QKPDGT VELLIYYT STLQSGVPS R FSGSGSGTD YSLTIS NLE PED IG TYYCQQ YSKLPRTFGGGT KLEI K |
Indusatumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | QVQLQQWGAGLLKPSETLSLTCAVFGGSFSGYYWSWIRQPPGKGLEWIGEINHRGNTNDNPSLKSRVTISVDTSKNQFALKLSSVTAADTAVYYCARERGYTYGNFDHWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSRNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIGSLQSEDFAVYYCQQYKTWPRTFGQGTNVEIK | na | na | null | null | null | 2,014 | 2015 | GUCY2C | Millennium;Takeda Oncology | na | na | Colorectal cancer;Gastrointestinal cancer;Pancreatic cancer | na | null | QV QLQQW GAGLLKPSE TLSLTCAVF GGSFSG YYWSWIR QPPGKGL EWIGEIN HRGNTNDNPSLK SRVTISVD TSKN QFALKLSS VTAA DTA VYYC ARE RGY TY GNFDHWGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCR ASQSVSRN LAW Y QQKPGQAP RLLIYG ASTRATGIP ARF SGSGSGT EFTLTIG SLQSED FAVYYCQ QYKTWPRTFGQGT NVEI K |
Inebilizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS | EIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2016 | CD19 | Cellective Therapeutics;MedImmune | Neuromyelitis optica | Autoimmune disorders;Myasthenia gravis;Renal transplant rejection | B-cell lymphoma;Chronic lymphocytic leukaemia;Diffuse large B-cell lymphoma;Follicular lymphoma;Multiple myeloma;Multiple sclerosis;Systemic scleroderma | POTELLIGENT Technology | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFS SSW MNWVR QAPGKG LEWVGRI YPGDGDTN YNVKFKGRFTISR DDSKN SLYLQMN SLKTEDT AVYYC ARSG FITTVRD FDYWGQG TLVTVS S | E IVLTQ SPDFQSVTPKE KVTITCR ASESVD TFGISFMN WF QQKPDQSP KLLIHE ASNQGSGVPS R FSGSGSGTD FTLTIN SLE AEDAATYYCQ QSKEVP FTF GGG TKVEI K |
Inezetamab | Bispecific Mixed mAb and scFv | G1;na | Lambda;Kappa | TBC | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSRNAMSWVRQAPGKGLEWVSATGGSGISTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYSNSWWYFDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGNYNLVSWYQQHPGKAPKLMIFEVNQRPSGVSNRFSGSKSGTTASLTISGLQAADEADYFCSSYTTSSTYVIFGGGTKLTVL | QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKCLEWISYISSSESIIYYVDAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDVGSHFDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLISAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQAKSFPRTFGCGTKVEIK | None;None | None;None | None;None | 2,022 | na | CD40;MSLN | TBC | TBC | TBC | TBC | TBC | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFS RNA MSWVR QAPGKG LEWVSA TGGSGI STYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RGYSNS WWYFD YWGQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCT GTSSDVGN YNLVSWY Q QHPGKAP KLMIFEV NQRPSGVSNRFSGSKSGT TASLTIS GLQAADEAD YFCSS YTTSS TYVIF GGGT KLTV L |
Infliximab | Whole mAb | G1 | Kappa | Approved | NFD | EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS | DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK | na | na | 5vh3:HL:AB/5vh4:HL:AB/4g3y:HL/6ugs:HL:AB/6ugv:HL:AB/6ugt:HL:AB/6ugu:HL:AB | null | null | 1,997 | 1998 | TNFA | Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen | Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Mucocutaneous lymph node syndrome;Plaque psoriasis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis | na | Berylliosis;Hepatitis C;Pyoderma | na | null | E VKLEE SGGG LV QPGGS MKLSCVA SG FIF SNH WMNWVR QSPEKGL EWVAEIR SKSINSAT HYAES VKG RFTISR DDSKS AVYLQMT DLRTEDTG VYYCSR NYYGST Y DYWGQG TTLTVS S | D ILLT QSP AILSV SPGE RVSFSCR ASQFVGS SIHWYQQ RTNGSP RLLIKYA SESMSGIPSRFSGSGSGT DFTLSINTV ESE DIADYYC QQSHSWP FTF GSGT NLEV K |
Inotuzumab | Whole mAb ADC | G4 | Kappa | Approved | Active | EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS | DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK | na | na | null | null | null | 2,004 | 2005 | CD22 | Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group | Precursor cell lymphoblastic leukaemia-lymphoma | Precursor B-cell lymphoblastic leukaemia-lymphoma;Chronic myeloid leukaemia | Acute biphenotypic leukaemia;Burkitt's lymphoma;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY RFTNYWIHWVR QAPGQG LEWIGGI NPGNNY ATYRRKF QG RVTMTA DTSTS TVYMELS SLRSEDT AVYYCT REGYGNYG AWFAYW GQG TLVTVS S | DV QVT QSPSS LSA SVGD RVTITCR SSQSLANSYGN TFLSWYL HKPGKAP QLLIYGI SNRFSGVPDRFSGSGSGT DFTLTISS LQPEDF ATYYCL QGTHQP YT FGQGT KVEI K |
Intetumumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK | na | na | null | null | null | 2,009 | 2010 | ITGAV_ITGB3 | Centocor Inc;Janssen Biotech;Janssen-Cilag | na | na | Malignant melanoma;Prostate cancer | VelocImmune Mouse | null | Q VQLVES GGG VV QPGRS RRLSC AASGF TFSRYTMHWVRQ APGKGL EWVAVISF DGSNK YYVD SVKG RFTISR DNSEN TLYLQVNILR AEDT AVYYCAR EARGS YAFDIW GQG TMVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSYL A W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPFTFGPGT KVD IK |
Iparomlimab | Whole mAb | G4 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVRQAPGQGLEWMGEIDPYDSYTNYNQKFKGRVTMTVDKSTSTVYMELSSLRSEDTAVYYCARPGFTYGGMDFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKSSQSLFNSGNQKNYLAWYQQKPGKVPKLLIYGASTRDSGVPYRFSGSGSGTDFTLTISSLQPEDVATYYCQNDHYYPYTFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | PDCD1 | Qilu Puget Sound Biotherapeutics | na | Neoplasms | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYWIHWVR QAPGQGL EWMGEI DPYDSYTNYNQKFKG RVTMTVD KSTS TVYMELS SLRSEDT AVYYCA RPGF TY GG MD FWGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITC KSSQS L FNSGN QKNYLAWYQ QKPGKVP KLLIYG ASTRDSGVP YRF SGSGSGTD FTLTIS SLQ PEDVAT YYC QNDHYYPY T FGGGT KVEI K |
Ipilimumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | 5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL | null | 7su0:HL:IM/7su1:HL | 2,005 | 2006 | CTLA4 | Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center | Malignant melanoma;Renal cell carcinoma | Colorectal cancer;Non-small cell lung cancer;Gastric cancer;Glioblastoma;Head and neck cancer;Mesothelioma;Oesophageal cancer;Prostate cancer;Small cell lung cancer;Urogenital cancer;Adrenocortical carcinoma;Breast cancer;CNS cancer;Gastrointestinal cancer;Genitourinary disorders;Gynaecological cancer;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Neuroendocrine tumours;Ovarian cancer;Pancreatic cancer;Penile cancer;Solid tumours;Thyroid cancer;Uveal melanoma;Diffuse large B cell lymphoma;Liver cancer;Lung cancer;Glioma | HIV infections;Lymphoma | Medarex UltiMAb Mouse | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSYTMHWVRQ APGKGL EWVTFISY DGNNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AIYYCA RTGWLGPFDYWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCRA SQSVGS SYLAWYQ QKPGQAP RLLIYGAF SRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYGSSPW TF GQGT KVEI K |
Iratumumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWSWIRQPPGKGLEWIGDINHGGGTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCASLTAYWGQGSLVTVSS | DIQMTQSPTSLSASVGDRVTITCRASQGISSWLTWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPITFGQGTRLEIK | na | na | null | null | null | 2,005 | 2006 | TNFRSF8 | Medarex | na | na | Hodgkin's disease;Lymphoma;Non-Hodgkin's lymphoma | Medarex UltiMAb Mouse | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGS FSAYYWSWIR QPPGKGL EWIGDI NHGGGTNYNPSLKS RVTISVD TSKN QFSLKL N S VTAADT AVYYCASLTAYW GQGS LVTV SS | DIQ MT QSPT SLSAS VGD RVTITCR ASQGIS SW LTWY QQKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQP EDFAT YYC QQYDSYP ITF GQGT RLEI K |
Isatuximab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS | DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK | na | na | 4cmh:BC | null | null | 2,014 | 2015 | CD38 | ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi | Multiple myeloma | Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Solid tumours;Urogenital cancer | Non-small cell lung cancer;Prostrate cancer;T-cell lymphoma | na | null | Q VQLVQ SGA EVA KPGT SVKLSCK ASGY TFTDYWMQWVK QRPGQG LEWIGTI YPGDGDTGY AQKF QG KATLTA DKSSK TVYMHLS SLASEDS AVYYCA RGDYYGSNSLDYWGQGT SVTVS S | D IVMTQ S HLSMS TSLGDP VSITCK ASQDV STVVAWYQ QKPGQSPR RLIYSASYRYIG VPDRFTGSGAGT DFTFTISSV QAED LAVYYCQ QHYSPPY T FGGGT KLEI K |
Iscalimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS | DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR | na | na | null | null | null | 2,017 | 2018 | CD40 | Novartis;XOMA | na | Graves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus | Rheumatoid arthritis | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY EESNR Y HADSV KGRFTIS RDNS KITLYLQM NSLRTEDT AVYYCA RDGG I AAPGPDYWGQG TLVTV SS | D IVMT QSPL SLTV TPGEP ASISCR SSQ SLLY SNGYN YLDWYL QKPGQSP QVLISL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQ ARQTPF TF GPGT KVD IR |
Isecarosmab | Bispecific Single Domains (VH-VH') | na;na | na;na | Phase-I | Active | DVQLVESGGGVVQPGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAGISRSAERTYYVDSLKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAADLDPNRIFSREEYAYWGQGTLVTVSS | na | EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS | na | None;None | None;None | None;None | 2,019 | 2020 | ADAMTSL5;ALB | Merck | na | Solid tumours | na | na | null | D VQLVES GGG VV QPGG SLRLSC AASGR TVSSYAMGWFR QAPGKE REFVAGIS RSAE RTYYVD SLKG RFTISR DNSKN TVYLQMN SLRPEDT ALYYCAA DLDPNRIFS REE YAYW GQG TLVTV SS | null |
Ispectamab | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNISAPGIHWVRQAPGKGLEWVGFINPAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDYIRQYWTYVLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | TNFRSF17 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGG SLRLSC AASGF NI SAPG IHWVRQ APGKG LEWVGFI NPAGGYTDYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYC ARD YIRQ YWTYVLDY WGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Istiratumab | Bispecific Mixed mAb and scFv | G1;na | Kappa;Lambda | Phase-II | Discontinued | EVQLLQSGGGLVQPGGSLRLSCAASGFMFSRYPMHWVRQAPGKGLEWVGSISGSGGATPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDFYQILTGNAFDYWGQGTTVTVSS | DIQMTQSPSSLSASLGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAKSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQYWTFPLTFGGGTKVEIK | QVQLVQSGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVAGISWDSGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGAYQWVEGFDYWGQGTLVTVSS | SYELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSTSGNSASLTITGAQAEDEADYYCNSRDSPGNQWVFGGGTKVTVL | None;None | None;None | None;None | 2,017 | 2018 | IGF1R;ERBB3 | Adimab;Merrimack Pharmaceuticals | na | na | Ovarian cancer;Pancreatic cancer;Solid tumours | na | null | E VQLLQS GGG LV QPGG SLRLSC AASGF MF SRYPM HWVRQ APGKG LEWVGSIS GSGGATPYADSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYC AKD F YQIL TGNAFDYWGQG TTVTVS S | DIQ MT QSPSS LSA SLGD RVTITCR ASQGIS SYLAWY QQKPGKAP KLLIYAK STLQSGVPS RF SGSGSGTD FTLTISS LQPEDSA TYYCQQYWTFPLTF GGG TKVEI K |
Itepekimab | Whole mAb | G4 | Kappa | Phase-III | Active | EVQLVESGGNLEQPGGSLRLSCTASGFTFSRSAMNWVRRAPGKGLEWVSGISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAAYYCAKDSYTTSWYGGMDVWGHGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGIFSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQANSVPITFGQGTRLEIK | na | na | null | null | null | 2,019 | 2020 | IL33 | Regeneron Pharmaceuticals;Sanofi | na | Chronic obstructive pulmonary disease | Allergic asthma;Inflammation;Asthma;Atopic dermatitis | na | null | E VQLVE SGGNLEQPGG SLRLSCT ASG FTFS RSAM NWVRR APGKGL EWVSGI SGSGGR TYYA DSVKG RFTISR DNSKN TLYLQMN SLS AEDTAA YYC AKDSYTTSWYGG MDV WGHG TTVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG IFSWLAWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPED FAIYYC QQANSV PITF GQGT RLEI K |
Itolizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQAPGKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASRDIRSYLTWYQQKPGKAPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGESPFTLGSGTKLEIK | na | na | null | null | null | 2,010 | 2011 | CD6 | Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium | Plaque psoriasis | Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis | Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis | na | null | E VQLVES GGG LV KPGG SLKLSC AASGF KFSRYAMSWVR QAPGK RLEWVATIS SGGS YIY YPDSVKG RFTIS RDNVKN TLYLQMS SLRSEDT AMYYCAR RDYDLDY F DSWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASRD IRSYL TWYQ QKPGKAPK TLIYYATS LADGVPS RF SGSGSGQD YSLTISS LESDDT ATYYCLQ HGESPF T LGSGT KLEI K |
Ivicentamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-I/II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYNMGWVRQAPGKGLEWVSVIDASGTTYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCARELLYFGSSYYDLWGQGTLVTVSS | DVVMTQSPSTLSASVGDRVTITCQASQNIDSNLAWYQQKPGKAPKFLIYYASNLPFGVPSRFKGSGSGTEFTLTISSLQPDDFATYYCQSADVGSTYVAAFGGGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFSLSYNAMNWVRQAPGKGLEWVSIIFASGRTDYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGSTWGDALDPWGQGTLVTVSS | AYDMTQSPSTLSASVGDRVTITCQASQNIIDYLAWYQQKPGKAPKLLIHKASTLASGVPSRFKGSGSGTEFTLTISSLQPDDFATYYCQQGYSNSNIDNTFGGGTKVEIK | None;None | None;None | None;None | 2,021 | 2022 | CD37;CD37 | Genmab | na | B cell Lymphoma | na | DuoBody | null | E VQLVES GGG LV QPGG SLRLSC AASGF S LSNY NMGWVRQ APGKGL EWVSVID ASGT TYYATW AKG RFTISR DNSKN TLYLQMNS LRAEDT ATYYCA R ELLYF GSS YY DLWGQG TLVTV SS | D VVMT QSPS TLSAS VGD RVTITCQ ASQNIDSN LAWYQ QKPGKAP KFLIYYA SNLPFGVPSRFKGSGSGT EFTLTISS LQPDDF ATYYCQS ADVGS TYVAAF GGG TKVEI K |
Ivonescimab | scFv-IGHC | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK | na | na | 1bj1:HL:KJ | null | 6bft:AB:HL/1cz8:HL:YX | 2,021 | 2022 | VEGFA | Akeso Biopharma | na | Non-small cell lung cancer;Solid tumours;Neoplasms;Gynecological Cancer | na | na | Bevacizumab and Ivonescimab have same Fv sequences | E VQLVES GGG LV QPGG SLRLSC AASGY TFTN YGM NWVRQ APGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPHYYGSS HWYFDV WGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K |
Ivuxolimab | Whole mAb | G2 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIDYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARESGWYLFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | TNFRSF4 | Pfizer;Dana-Farber Cancer Institute;M. D. Anderson Cancer Center;National Cancer Institute USA;University of Southern California | na | Breast cancer;Renal cell carcinoma;Solid tumours;Acute myeloid leukaemia;Squamous cell cancer;Follicular lymphoma | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKGL EWVSYIS SSSST ID YADSVKG RFTISR DNAKNS LYLQMN SLRDEDT AVYYCA RESG WYLFDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATY Y CQQ YNSYPPTFGGGT KVEI K |
Ixekizumab | Whole mAb | G4 | Kappa | Approved | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK | na | na | 6nov:AB:CD | 6nou:AA | null | 2,011 | 2012 | IL17A | Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical | Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis | Ankylosing spondylitis;Spondylarthritis;Bullous pemphigoid;Pityriasis rubra pilaris;Pyoderma gangrenosum;Rheumatoid arthritis | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGYSFTD YHIHWVRQ APGQG LEWMGVI NPMYGTTDYNQR F K GRVTITA DESTS TAYMELSS LRSEDT AVYYCARYD YFTGT GVYW GQG TLVTVS S | DI VMT QTP LSLSV TPGQP ASISC RSSR SLVH SRGN TYLHWYLQ KPGQSP QLLIYKV SNR FIG VPDRFSGSGSGT DFTLKISRVE AEDV GVYYC SQSTHLPF TF GQGT KLEI K |
Izalontamab | Bispecific Mixed mAb and scFv | G1;na | Kappa;Lambda | TBC | Active | QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSS | DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK | QVQLQESGGGLVKPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARDRGVGYFDLWGRGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSSSTHVIFGGGTKVTVL | 5etu:DC:BA/5ff6:DC:BA/5f88:DC:BA/5itf:DC:BA/5ivz:DC:BA/5ir1:DC:BA/5esq:DC:BA/5euk:DC:BA/5hpm:DC:BA/5id1:DC:BA/5icx:DC:BA/5hyq:DC:BA/5icz:DC:BA/5th2:DC:BA/5iop:DC:BA/5i2i:DC:BA/5t1l:DC:BA/5i76:DC:BA/5iv2:DC:BA/5t1k:DC:BA;None | 6azk:DC:BA/6azl:BA:DC/6au5:DC:BA/6ayn:BA:DC/6axp:BA:DC/5id0:DC:BA/5t1m:DC:BA/5icy:DC:BA/1yy8:DC:BA/1yy9:DC/4gw5:DC:BA/4kro:DC/4gw1:DC:BA/4krp:DC;None | 5gz0:BA:DC/6arp:BA:DC/6aru:CB;None | 2,022 | na | EGFR;ERBB3 | TBC | TBC | TBC | TBC | TBC | Arm 1 is highly identical to cetuximab | QV QLKQ SGPGLVQPSQ SLSITCTV SGF SL T N Y GVHWVRQ SPGKGL EWLGVIWS GGNTDYNTPF TSRLSI NKDNSKS QVFFKM NSLQSNDT AIYYCA RAL TY YD YEFAYW GQG TLVTVS S | DI LLT QSP VILSV SPGE RVSFSCR ASQSIGT NIHWYQQ RTNGSP RLLIKYA SESISGIPSRFSGSGSGT DFTLSIN SVES EDIADYYCQ QNNNWPTTFGAGT KLEL K |
Izeltabart | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLEWVGEIIPIFGHTNYNEKFKSRFTISLDNSKNTLYLQMGSLRAEDTAVYYCARGGYYYYPRQGFLDYWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATISCKASQSVDYSGDSYMNWYQQKPGQPPKLLIYAASDLESGIPARFSGSGSGTDFTLTISSLEPEDFATYYCQQSHEDPFTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | ADAM9 | TBC | TBC | TBC | TBC | Humanised | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSSYWMHWVR QAPGKGL EWVGEIIPIF GHTNYNEKFK SRFTISL DNSKN TLYLQMG S L RAEDT AVYYC ARGG YYYY PRQGF LDY WGQG TTVTVS S | D IVMT QSPDS LAVS LGER ATISCK ASQS V DYSGDS YMNWYQ QKPGQPP KLLIYAA SDLESGIP ARFS GSGSGTD FTLTIS SLEPE DF ATYYCQ QSHEDPFTFGQGT KLEI K |
Izenivetmab | Canine Whole mAb | G2 | Kappa | Unknown | Active | EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRSGYDYYFDVWGQGTLVTVSS | EIVMTQSPASLSLSQEEKVTITCRASENIYSFLAWYQQKPGQAPKLLIYNANTLAEGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQHHFGTPFTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | NGFB (Canine) | TBC | TBC | TBC | TBC | TBC | null | E VQLVE SGGD LV KPGG SLRLSCVA SGF TF SN YWMHWVRQ APGKG LQWVARI DPYGGGTKHNEK FKRRFTISR DNAKN TLYLQMN SLRAEDT AMYYCVR SGYD YYFDVW GQG TLVTVS S | E IVMT QSPASL S LSQEE KVTITCR ASEN IYSFLAWY QQKPGQAP KLLIYN ANTLAEGVPSRFSGSGSGTD FSFTIS SLEPED VAVYYCQ HHFGTPF T FGQGT KLEI K |
Izuralimab | Bispecific Mixed mAb and scFv | G1;na | Kappa;Kappa | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPHSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARTYYYDSSGYYHDAFDIWGQGTMVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISRLLAWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK | EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS | EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK | None;None | None;None | None;None | 2,020 | 2021 | ICOS;PDCD1 | Xencor | na | Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPHSGGTNY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCARTYYY DSSGY YHDAFDI WGQG TMVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRLLAWYQ QKPGKAP KLLIYVA SSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YC QQANSFPW T FGQGT KVEI K |
Labetuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMSWVRQAPGKGLEWIGEIHPDSSTINYAPSLKDRFTISRDNAKNTLFLQMDSLRPEDTGVYFCASLYFGFPWFAYWGQGTPVTVSS | DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAWYQQKPGKAPKLLIYWTSTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYSLYRSFGQGTKVEIK | na | na | null | null | null | 2,015 | 2016 | CEACAM5 | Immunomedics | na | na | Colorectal cancer;Ovarian cancer;Breast cancer | na | null | E VQLVES GGG VV QPGR SLRLSCS ASGFD FTTYWMSWVR QAPGKGL EWIGEI HPDSST IN YAPSLKD RFTISR DNAKN TLFLQM DSLRPEDTG VYFCASLY FGFPW FAYW GQGT PVTV SS | DI QLT QSPSS LSA SVGD RVTITCK ASQDVGT SVAWYQ QKPGKAP KLLIYWT STRHTGVPSRFSGSGSGT DFTFTIS SLQ PEDIATYYCQQ YS LYRS FGQGT KVEI K |
Lacnotuzumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLQESGPGLVKPSQTLSLTCTVSDYSITSDYAWNWIRQFPGKGLEWMGYISYSGSTSYNPSLKSRITISRDTSKNQFSLQLNSVTAADTAVYYCASFDYAHAMDYWGQGTTVTVSS | DIVLTQSPAFLSVTPGEKVTFTCQASQSIGTSIHWYQQKTDQAPKLLIKYASESISGIPSRFSGSGSGTDFTLTISSVEAEDAADYYCQQINSWPTTFGGGTKLEIK | na | na | null | null | null | 2,016 | 2017 | CSF1 | Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital | na | Breast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours | Bone metastases;Prostate cancer | na | null | QV QLQE SGPGLVKPSQ TLSLTCTV SDYS I TSD YAWNWIRQ FPGKGL EWMGYISY SGSTSYNPSLK SRITISR DTSKN QFSLQLN S V TAADT AVYYCAS FDYA H AMDYWGQG TTVTVS S | D IVLT QSPA FLSV TPGE KVTFTCQ ASQSIGT SIHWYQ QKTDQAP KLLIKYA SESISGIPSRFSGSGSGTD FTLTISSV EAEDA ADY YCQQ INSWPTTFGGGT KLEI K |
Lacutamab | Whole mAb | G1 | Kappa | Phase-II | Active | QIQLVQSGSELKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWIGWINSHSGVPKYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARGGDEGVMDYWGQGTTVTVSS | DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGQPPKLLIYWTSTRHTGVPDRFSGSGSGTDYTLTISSLQAEDVAVYYCQQHYSTPWTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | KIR3DL2 | University of Genoa;Innate Pharma | na | Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome | na | na | null | Q IQLVQ SGS E LKKPGA SVKVSCK ASGY TFTT AG MQWVRQ APGQGL EWIGWIN SHSGVPKYAEDFKG RFVFSL DTSVS TAYLQISS LKAED TAVYFCA RGGDEGV MDY WGQG TTVTVS S | DIQ M TQSPS FLSA SVGD RVTITCK ASQDV S TAVAWYQ QKPGQPP KLLIYWT STRHTGVPDRFSGSGSGTD YTLTISS LQAED VAVYYCQ QHYSTPW T FGGG TKVEI K |
Ladiratuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS | DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRPLIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIK | na | na | null | null | null | 2,017 | 2018 | SLC39A6 | Merck & Co;Quantum Leap Healthcare Collaborative;Seattle Genetics | na | Breast cancer | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGLT IE D YYMHWVR QAPGQG LEWMGWI DPENGDTEYGPK FQGRVTMT RDTSI NTAYMELSR LRSDDT AVYYCAVH NAHYG TWFAYW GQG TLVTVS S | DV VMT QSPLSLP VT LGQPA SISC RSSQ SLLH SSGN TYLEWYQ QRPGQSPRP LIYKISTR FSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVP YTF GGG TKVEI K |
Lampalizumab | Fab | G1 | Kappa | Phase-III | Discontinued | EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS | DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK | na | na | 4d9q:HL:ED/4d9r:HL:ED | null | null | 2,012 | 2013 | CFD | Tanox;Genentech | na | na | Dry age-related macular degeneration | na | Erroneously dropped during Feb '22 update. Readded August '22. | E VQLVQ SGPELKKPGA SVKVSCK ASGY TFTN YG MNWVR QAPGQGL EWMGWIN TYTGE TTYA DDFKG RFVFSL DTSVS TAYLQISS LKAED TAVYYCER EGGVNNWGQG TLVTVS S | DI QVT QSPSS LSA SVGD RVTITCIT STDIDDDMN WY QQKPGKVP KLLIS GGNTLRPGVPSRFSGSGSGTD FTLTIS SLQPED V ATYYCL QSDSLPY T FGQGT KVEI K |
Lanadelumab | Whole mAb | G1 | Kappa | Approved | NFD | EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK | na | na | 4pub:HL/4ogy:HL:MN/4ogx:HL | null | null | 2,015 | 2016 | KLKB1 | Dyax;Shire;Takeda | Hereditary angioedema | na | Diabetic macular oedema | na | null | E VQLLES GGG LV QPGG SLRLSCA ASGF TFSHYIMMWVRQ APGKG LEWVSGIY SSGG ITVYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAYRR IGVPRRDE FDIW GQG TMVTVS S | DIQ MT QSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KLLIYK ASTLESGVPS R FSGSGSGT EFTLTIS SLQPDD FA TYYCQ QYNT YWTF GQGT KVEI K |
Landogrozumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGLTFSRYPMSWVRQAPGKGLVWVSAITSSGGSTYYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARLPDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASSSVSSSYLHWYQQKPGQAPRLLIYSTSNLVAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHHSGYHFTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2016 | MSTN | Eli Lilly | na | na | Cancer;Cachexia;Muscular atrophy;Pancreatic cancer | na | null | E VQLVES GGG LV QPGG SLRLSC AASGL TFS RYPM SWVR QAPGKG LVWVSAIT SSGGS TYYS DTVK GRFTISR DNAKN TLYLQMNS LRAEDT AVYYCAR LPDYWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCRA SSSVSSS YLHWYQ QKPGQAP RLLIYS TSNL VA GIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ HHSG YHFTF GGG TKVEI K |
Laprituximab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDINNYLAWYQHKPGKGPKLLIHYTSTLHPGIPSRFSGSGSGRDYSFSISSLEPEDIATYYCLQYDNLLYTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2016 | EGFR | ImmunoGen | na | na | Solid tumours | na | null | Q VQLVQ SGA EVA KPGA SVKLSCK ASGY TFTSYWMQWVK QRPGQG LECIGTIY PGDGDT TYTQKF QG KATLTA DKSSST AYMQLSS LRSEDS AVYYCAR YDAPGY AMDY WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQD INNY LAWYQ HKPGKGP KLLIHYTS TLHPGIPSRFSGSGSGRD YSFSIS SLE PEDI ATYYCLQ YDN LLYTF GQGT KLEI K |
Larcaviximab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLQESGPELEMPGASVKISCKASGSSFTGFSMNWVKQSNGKSLEWIGNIDTYYGGTTYNQKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSAYYGSTFAYWGQGTLVTVSA | DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLIEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYFCQHHFGTPFTFGSGTELEIK | na | na | null | 5ken:CD:GH:NO | null | 2,016 | 2017 | Zaire Ebolavirus GP | Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases | na | Ebola virus infections | na | Zmapp Technology | null | EV QLQ ESGPEL E MPGA SVKISCK ASGSS FTGFSMNWVK QSNGK SLEWIGNID TYYGGTTYNQK F KG KATLTVD KSSST AYMQLKS LTSEDS AVYYCAR SAYYGS TFAYW GQG TLVTVS A | DIQ MT QSPA SLSA SVGE TVTITCR ASEN IYSYLAWYQQK QGKSP QLLVYN AK TLI EGVPSRFSGSGSGT QFSLKI NSLQP ED FGSY FCQ HHFGTPF T FGSGT ELEI K |
Latikafusp | Whole mAb Fusion | G1 | Lambda | TBC | Active | EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSGINWNAGRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREFNNFESNWFDPWGQGTLVTVSS | SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISEDAKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFGGGTKLTVL | na | na | null | null | null | 2,022 | na | PDCD1 | TBC | TBC | TBC | TBC | TBC | null | E VQLVE SGG SVV RPGG SLRLSC AASGF TV DDY SMSWVRQ VPGKG LEWVSGIN WNAGRT RYA DAVKG RFTISR DSAKNS LYLQMN SLRAEDT ALYYCAR EFNNFESNW F DPWGQG TLVTVS S | SYELTQPPS VSV SPGQ TARITC SGDALPKK YAYWYQ QKPGQAP VLVIS EDAKRPSGIPERFSGSSSGT MATLTI SGA Q VEDEAD YYCYST DASGN HRVFG GGT KLTV L |
Latozinemab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGTIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQGSIKQGYYGMDVWGQGTTVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSTGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRAEAEDVGVYYCMQQQEAPLTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | SORT1 | Alector | na | Frontotemporal dementia | na | na | null | QV QLQ ESGPGL V KPSE TLSLTCAV SGY SI SSG YYWGWIR QPPGKGL EWIGTIYH SGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAAD TAVYYCA RQGS IK QG YYGMDV WGQG TTVTVS S | DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLRS TGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKIS RAEA EDV GVYYCM QQQEAP LTF GGG TKVEI K |
Lebrikizumab | Whole mAb | G4 | Kappa | Phase-III | Active | QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS | DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK | na | na | 4i77:HL | null | null | 2,009 | 2010 | IL13 | Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox | na | Atopic dermatitis | Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis | na | null | Q VTLRE SGPA LV KPTQ TLTLTCTV SGF SLSAYSVNWIR QPPGKA LEWLAMIW GDG KIVYN SALKS RLTIS KDTSKN QVVLTMT NMDPVDT ATYYC AGDGYYPYAMDNWGQG SLVTV SS | D IVMT QSPDS LSVS LGER ATINCR ASKSVDSYGN SFMHWYQ QKPGQPP KLLIYLA SNLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNNEDPRTFGGG TKVEI K |
Lecanemab | Whole mAb | G1 | Kappa | Preregistration | Active | EVQLVESGGGLVQPGGSLRLSCSASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTIYYGDTVKGRFTISRDNAKNSLFLQMSSLRAEDTAVYYCAREGGYYYGRSYYTMDYWGQGTTVTVSS | DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIK | na | na | null | null | null | 2,019 | 2020 | APP | Biogen;Eisai | na | Alzheimer's disease;Brain injuries;Down syndrome | na | na | (June '22: Corrected FWL3 sequence) | E VQLVES GGG LV QPGG SLRLSCS ASGF TFSS F GMHWVRQ APGKG LEWVAYIS SGSS TIYY GD TVKGRFTISR DNAKNS LFLQMSS LRAEDT AVYYCA REGG YYY G RSYYTMD YWGQG TTVTVS S | DV VMT QSPLSLPVTPGAPA SISC RSSQ SIVH SNGN TYLEWYL QKPGQSP KLLIYKVS NRFSGVPDRFSGSGSGT DFTLRISRVE AEDV GIYYCF QGSHVPPTFGPGT KLEI K |
Lemalesomab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLQESGPELKKPGETVKISCKASGYTFRNYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNVKNEDTATYFCARKGWMDFNGSSLDYWGQGTTVTVSS | DIQLTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPNLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK | na | na | null | null | null | 2,002 | 2002 | NCA90 | ND | na | na | Diagnosis of Lesions | na | null | QV QLQ ESGPELKKPGE TVKISCK ASGY TFRN YGM NWVK QAPGKGL KWMGWIN TYTGEPTYADDFKG RFAFSLET SAS TAYLQIN NVKNEDTA TYFCAR KGW M DFNGS SLDY WGQG TTVTVS S | DI QLT QTPLSLPVSLGDQ ASISC RSSQ SIVH SNGN TYLEWYL QKPGQSPN LLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GVYYCF QGSHVPPTFGGGT KLEI K |
Lemzoparlimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGLTFERAWMNWVRQAPGKGLEWVGRIKRKTDGETTDYAAPVKGRFSISRDDSKNTLYLQMNSLKTEDTAVYYCAGSNRAFDIWGQGTMVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLYAGNNRNYLAWYQQKPGQPPKLLINQASTRASGVPDRFSGSGSGTEFTLIISSLQAEDVAIYYCQQYYTPPLAFGGGTKLEIK | na | na | null | null | null | 2,020 | 2021 | CD47 | I-Mab Biopharma | na | Lymphoma;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGLT FER A WMNWVR QAPGKGL EWVGRIKR KTDGETTDYAAP V K GRFSISR DDSKN TLYLQMN SLKTEDT AVYYC AGSNR AFDIW GQG TMVTVS S | D IVMT QSPDS LAVS LGER ATINC KSSQ SVLYA GNNRN YLAWYQ QKPGQPP KLLIN QASTRASGVPDRFSGSGSGT EFTLIISS LQAED VAIYYCQQ YYTPPL A FGGGT KLEI K |
Lenvervimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVKPGGSLRLSCSASGFSLTKYKMTWVRQAPGKGLEWVSSISSTSRDIDYADSVKGRFTISRDNAKNSLFLQMSSLRVDDTAVYYCTRDGWLWGWDVRSNYYYNALDVWGQGTTVTVSS | DIVVTQSPSSLSASVGDRVTITCRASQGIYNSIAWYQQKPGKAPKLLLYSTSTLLSGVPSRFSGSGSGTDYTLTITNLQPEDFATYYCQQYFVTPETFGQGTKLEIK | na | na | null | null | null | 2,017 | 2018 | HBV | Green Cross;GC Pharma;AbbVie | na | Hepatitis B | na | na | null | E VQLVES GGG LV KPGG SLRLSCS ASGFS L T KYKMTWVRQ APGKG LEWVSSIS STSRDIDYADSVKG RFTISR DNAKNS LFLQMSSLRV DDT AVYYC TRDG WLWGWD VRSN YYYNALDV WGQG TTVTVS S | D IVVTQ SPSS LSA SVGD RVTITCR ASQGI YNSIAWYQ QKPGKAP KLLLYS TSTL L SGVPSRFSGSGSGTD YTLTIT NLQ PEDFAT YYCQQYF VTPE T FGQGT KLEI K |
Lenzilumab | Whole mAb | G1 | Kappa | Preregistration | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS | EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK | na | na | null | null | null | 2,014 | 2015 | CSF2 | Humanigen;KaloBios Pharmaceuticals | na | COVID-19;Cytokine release syndrome;B-cell lymphoma;Drug hypersensitivity;Precursor cell lymphoblastic leukaemia-lymphoma;Graft-versus-host disease | Asthma;Rheumatoid arthritis;Chronic myelomonocytic leukaemia;Solid tumours | Humaneering Technology | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYS FTNYYIHWVR QAPGQ RLEWMGWIN AGNGNTK YSQKF QG RVTITR DTSAS TAYMELS SLRSEDT AVYYCVR RQRFPY YFDY WGQG TLVTVS S | E IVLTQ SPA TLSV SPGE RATLSCR ASQSVGT NVAWYQ QKPGQAP RVLIYS TSSRATG ITD RFSGSGSGT DFTLTISR LEPED FAVYYCQ QFNKSPL TF GGG TKVEI K |
Lepunafusp | Whole mAb Fusion | G1 | Kappa | Phase-I/II | Active | EVQLVQSGAEVKKPGESLKISCKGSGYSFMNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQLSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK | na | na | null | null | null | 2,021 | 2022 | TfR1 | JCR Pharmaceuticals | na | Mucopolysaccharidosis I | na | na | null | E VQLVQ SGA EVK KPGE SLKISC KGSGYS FMNYWL GWVR QMPGKGL EWMGDI YPGGDYPTYSEK FKVQVTIS ADKS ISTAYLQLS SLKASDT AMYYCA RSGNYD EVAYW GQG TLVTV SS | DI VMT QTP LSLSV TPGQP ASISCR SSQ SLVH SNGN TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCS QSTHVPW T FGQGT KVEI K |
Lerdelimumab | Whole mAb | G4 | Lambda | Phase-III | Discontinued | EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCGRTLESSLWGQGTLVTVSS | SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSSTHRGVFGGGTKLTVL | na | na | null | null | null | 2,002 | 2002 | TGFB1 | Cambridge Antibody Technology | na | na | Cataracts;Proliferative vitreoretinopathy;Scars | na | null | E VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMD SLRAED TAVYYC GR TLES S L WGQG TLVTVS S | SSELTQDPA VSVA LGQ TVRITC QGDS LRSYYASWY QQKPGQAP VLVIY GKNNRPSGIPDRFSGSSSGN TASLTIT GAQAEDEAD YYC NSRDSSSTHRG VF GGGT KLTV L |
Leronlimab | Whole mAb | G4 | Kappa | Approved | Active | EVQLVESGGGLVKPGGSLRLSCAASGYTFSNYWIGWVRQAPGKGLEWIGDIYPGGNYIRNNEKFKDKTTLSADTSKNTAYLQMNSLKTEDTAVYYCGSSFGSNYVFAWFTYWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQRLLSSYGHTYLHWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | CCR5 | CytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute | Breast cancer | HIV infections;HIV-1 infections;Graft-versus-host disease;Colorectal cancer;Non-alcoholic steatohepatitis;Prostate cancer;COVID-19;Autoimmune disorders;Stroke;Traumatic brain injuries | na | na | null | E VQLVES GGG LV KPGG SLRLSCA ASGY TF SN YWIGWVRQ APGKGL EWIGDI YPGGN YIR NNEKFKDK TTLSA DTSKN TAYLQM NSLKTEDT AVYYC GSSFGSN YVFAWFTY WGQG TLVTVS S | DI VMT QSPLSLPVTPGEPA SISC RSSQ RLLS SYGH TYLHWYL QKPGQSP QLLIYEVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYC SQSTHVP LTF GQGT KVEI K |
Lesabelimab | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYYWGWIRQAPGKGLEWIGIIYPSGGGTNYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARGGGLGFDYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCRASQSIPSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHYISWPRQFTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | CD274 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGG SLRLSC AASGY SI SSG YYWGWIRQ APGKGL EWIGIIY PSGGGTNYA QKF Q GRVTISR DNSKN TLYLQLNS LRAEDT AVYYCA RGGGLG FDY WGQG TLVTV SS | DI QLT QSPSS LSA SVGD RVTITCR ASQSI PSFLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQH Y ISWPR QFTF GQGT KVEI K |
Lesofavumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVQSGAEVKKPGESLKISCKVSGYSFTSQWIGWVRQMPGKGLEWIGMMYPGESETIYSPSFQGQVTISADNSISTAYLQWSSLKASDTAIYYCASGPGYSGYHYGWFDTWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK | na | na | null | null | null | 2,016 | 2017 | Influenza B Virus | Genentech | na | na | Influenza B virus infections | na | null | E VQLVQ SGA EVK KPGE SLKISCKV SGY SF TS QWIGWVRQ MPGKGL EWIGMM YPGESE TIY SPSFQG QVTIS ADNS ISTAYLQWS SLKASDT AIYYC ASGPGYSG YHYGWF DTWGQG TLVTVS S | DI VMT QSPLSLPVTPGEPA SISC RSS QSLLR SNGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQA LQTPY T FGQGT KLEI K |
Letaplimab | Whole mAb | G4 | Kappa | Phase-I/II | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | CD47 | Innovent Biologics | na | Acute myeloid leukaemia;Lymphoma;Myelodysplastic syndromes;Solid tumours | na | na | null | Q VQLQE SGPGL V KPSE TLSLTCTV SGGS I S SYYWSWIR QPPGKGL EWIGYIYYS GSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGKTGSAAWGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRWLAWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQ TVSFPITF GGG TKVEI K |
Letolizumab | Single Domain Variable Fragment;H | G1 | na | Phase-I/II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFNWELMGWARQAPGKGLEWVSGIEGPGDVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKVGKDAKSDYRGQGTLVTVSS | na | na | na | null | null | null | 2,016 | 2017 | CD40LG | Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute | na | Graft-versus-host disease;Idiopathic thrombocytopenic purpura | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFNWELMGWAR QAPGKG LEWVS GIEGPGD VTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCVKV GKDAKSDYRGQ GTLVTVS S | null |
Levilimab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIYSDGTTHYGDSVKGRFTISRDNAKNTVYLQLNSLRAEDTAMYYCAKGAGPTWWYALDAWGQGTLVTVSS | DIQLTQSPSSVSVSVGERVTIDCKSSQSVLSASNTYLNWYQQKPGQAPQLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDAAVYYCQQAYRAPVTFGQGTKLEIK | na | na | null | null | null | 2,018 | 2019 | IL6R | Biocad | COVID-19;Cytokine release syndrome | Rheumatoid arthritis | na | na | null | Q VQLVQS GGG LV QPGG SLRLSC AASGF TFSSYYMSWVR QAPGKG LEWVSGIY SDGT T HYGDS VKGRFTISR DNAKN TVYLQLNS LRAEDT AMYYCA KGAGPT WWYALD AWGQG TLVTVS S | DI QLT QSPS SVSVS VGE RVTID CKSSQS VLS ASNT YLNWY QQKPGQAP QLLIYYA STRESGVPDRFSGSGSGTD FTLTISS LQAEDA AVYYCQQ AYRAP VTF GQGT KLEI K |
Lexatumumab | Whole mAb | G1 | Lambda | Phase-I | Discontinued | EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS | SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL | na | na | null | null | 4od2:BA | 2,006 | 2007 | TNFRSF10B | Cambridge Antibody Technology;Human Genome Sciences | na | na | Solid tumours | na | null | E VQLVQS GGG VE RPGG SLRLSC AASGF TF DDYGM SWVRQ APGKGL EWVSGIN WNGGSTGYADSVKG RVTISR DNAKN SLYLQMN SLRAEDT AVYYCAKIL GAGRG WYFDL WGKG TTVTVS S | SSELTQDPA VSVA LGQ TVRITC QGDS LRSY Y ASWY QQKPGQAP VLVIY GKNNRPSGIPDRFSGSSSGN TASLTIT GAQAEDEA DYYCN SRDSSGN HVVF GGGT KLTV L |
Libivirumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVESGGGVVRPGRSLRLSCAASGFAFSDYSINWVRQAPGKGLEWVAIISYDGRITYYRDSVKGRFTISRDDSKNTLYLQMNSLRTEDTAVYYCARQYYDFWSGSSVGRNYDGMDVWGLGTTVTVSS | DIVMTQSPLSLSVTPGEPASISCRSSQSLLHRSGNNYLDWYLQKPGHSPQLLIYVGSNRASGVPDRFSGSGSGTEYTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKLEIK | na | na | null | null | null | 2,004 | 2005 | Hepatitis B Surface Antigen | XTL Biopharmaceuticals;Yeda | na | na | Hepatitis B infection | na | null | Q VQLVES GG GVV RPGR SLRLSC AASGF AF SDY SINWVRQ APGKGL EWVAIIS YDG RITYYR DSVKG RFTISR DDSKN TLYLQMN SLRTEDT AVYYCARQYY DFWSGSSVGRNYDGM DVW GLG TTVTVS S | D IVMT QSPL SLSV TPGEP ASISCR SSQS LLH RSGNN YLDWYL QKPGHSP QLLIYVG SNRASGVPDRFSGSGSGT EYTLKISRVE AEDV GVYYCMQA LQTPRTFGQGT KLEI K |
Licaminlimab | scFv | na | Lambda | Phase-II | Active | EVQLVESGGGSVQPGGSLRLSCTASGFTISRSYWICWVRQAPGKGLEWVGCIYGDNDITPLYANWAKGRFTISRDTSKNTVYLQMNSLRAEDTATYYCARLGYADYAYDLWGQGTTVTVSS | EIVMTQSPSTLSASVGDRVIITCQSSQSVYGNIWMAWYQQKPGRAPKLLIYQASKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQGNFNTGDRYAFGQGTKLTVL | na | na | null | null | null | 2,020 | 2021 | TNFA | Oculis | na | Dry eye syndrome | na | na | (Jan '22) Added missing FWH1 residue. (Jun '22) Corrected CDRH3 sequence | E VQLVES GGG SV QPGG SLRLSCT ASGF TIS R SYWICWVRQ APGKGL EWVGCIY GDNDITP LYAN WAKG RFTISR DTSKN TVYLQMN SLRA EDTATYYCAR LGYAD YAYDL WGQG TTVTVS S | E IVMT QSPS TLSAS VGD RVIITC QSSQSVYGN IWMAWY QQKPGRAP KLLIYQA SKLASGVPS RF SGSGSGA EFTLTISS LQPDDF ATYYCQ GNFNTGDR YAF GQGT KLTV L |
Lifastuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFAMSWVRQAPGKGLEWVATIGRVAFHTYYPDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHRGFDVGHFDFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSETLVHSSGNTYLEWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSFNPLTFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | SLC34A2 | Genentech | na | na | Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGFSFS DF AMSWVR QAPGKG LEWVATI G RVAFHTY YPDSMK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA R HRGF DVGHFDFW GQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCR SSE TLVH SSGN TYLEWYQ QKPGKAP KLLIYRVS NRFSGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYCF QGSFNPL T FGQGT KVEI K |
Ligelizumab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK | na | na | 6uqr:AA:CC | null | null | 2,012 | 2013 | IGHE | Novartis;Tanox | na | Urticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid | Hypersensitivity | na | null | Q VQLVQ SGA EVM KPGS SVKVSCK ASGY TFSWYWLEWVR QAPGHGL EWMGEI DPGT FTT NYNEK FKARVTFTA DTSTS TAYMELSS LRSEDT AVYYCARFS HFSGSNYD YFDY WGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCR ASQSIGT NIHWYQ QKPGQAP RLLIYYA SESISGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQ QSWSWPTTFGGG TKVEI K |
Ligufalimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMNWVRQRPGQGLEWIGMIDPSDSETHNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGTTVTVSS | NIVMTQSPATMSMSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHCGQSYNFPYTFGGGTKLEIK | na | na | null | null | null | 2,021 | 2022 | CD47 | Akeso Biopharma | na | Acute myeloid leukaemia;Neoplasms;Myelodysplastic syndromes | na | na | null | Q VQLVQ SGA EVV KPGA SVKLSCK ASGY TFTSYWMNWVR QRPGQGL EWIGMI DPSDSETHNAQKFQG KATLTVD KSTS TAYMHLS SLRSED TAVYYCARLYRWYFDV WGAGT TVTVS S | N IVMTQ SPA TMS MSPGE RVTLSCR ASE IVGTYVSWF QQKPGQAP RLLIYG ASNRYTGVP ARF SGSGSGTD FTLTISS VQ PEDL ADYHCGQSYNFPYTFGGGT KLEI K |
Lilotomab | Whole mAb ADC | G1 | Kappa | Phase-II | Active | EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS | DIVMTQSHKLLSTSVGDRVSITCKASQDVSTAVDWYQQKPGQSPKLLINWASTRHTGVPDRFTGSGSGTDYTLTISSMQAEDLALYYCRQHYSTPFTFGSGTKLEIK | na | na | null | null | null | 2,014 | 2015 | CD37 | Nordic Nanovector | na | Follicular lymphoma;Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma | na | na | null | EI QLQ QSGPE LV KPGA SVKVSCK ASGYSFTDY NMYWVK QSHGK SLEWIGYI DPYNGDTT Y NQ KF KG KATLTVD KSSS TAFIHLN SLTSEDS AVYYCAR SPYGH YAMD YWGQG TSVTVS S | DI VMT QSH KLLST SVGD RVSITCK ASQD VSTAVDWYQ QKPGQSP KLLINW ASTRHTGVPDRFTGSGSGTD YTLTISS MQ AEDLALYYCRQ HYSTPF TF GSGT KLEI K |
Linavonkibart | Whole mAb | G4 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCTASGFTFSSFSMDWVRQAPGKGLEWVSYISPSADTIYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGVLDYGDMLMPWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADNHPPWTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | TGFB1 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGG SLRLSCT ASG FTFSSFSMDWVR QAPGKGL EWVSYI SPSAD TIYYA DSVKG RFTISR DNAKN TLYLQMN SLRAEDT AVYYCA RGV L DYGD ML MPWGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCQ AS QDITNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCQ QADNHPPWTFGGGT KVEI K |